Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase NA 1Phase 3 1Phase 1/2 1Phase 1 1

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Dermatologic 2Sarcoma 1

Conditions

Carcinoma, Basal Cell 2Basal Cell Nevus Syndrome 2Bone Neoplasms 1

Interventions

Carboplatin 273Paclitaxel 267Gemcitabine 244Bevacizumab 226Cisplatin 218pembrolizumab 214Docetaxel 210Pemetrexed 162Capecitabine 148Fluorouracil 129Oxaliplatin 121Cyclophosphamide 121Nivolumab 112Dexamethasone 100Trastuzumab 89Leucovorin 87Cetuximab 85Rituximab 83Irinotecan 82Injections 81Erlotinib Hydrochloride 70Prednisone 68Doxorubicin 68Temozolomide 67atezolizumab 65Bortezomib 65Ipilimumab 64Fulvestrant 59Radiotherapy 54Drug Therapy 51

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × INDUSTRY × IPI-926 × Clear all
NCT02762084 2020-07-23

Trial of Patidegib Gel 2%, 4%, and Vehicle to Decrease the Number of Surgically Eligible Basal Cell Carcinomas in Gorlin Syndrome Patients

PellePharm, Inc.

Phase 2 Completed
17 enrolled 22 charts
Dermatologic

Basal Cell Nevus Syndrome, Carcinoma, Basal Cell

NCT02828111 2019-01-08

BCC

PellePharm, Inc.

Phase 2 Completed
36 enrolled 17 charts
Dermatologic

Basal Cell Nevus Syndrome, Carcinoma, Basal Cell

NCT01310816 2013-12-05

A Safety and Efficacy Study of Patients With Metastatic or Locally Advanced (Unresectable) Chondrosarcoma

Infinity Pharmaceuticals, Inc.

Phase 2 Completed
105 enrolled
Sarcoma

Bone Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡